Burning Rock Dx(US:BNR) Jin Rong Jie·2025-08-12 18:41Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.98% to $7.147 per share, with a total market capitalization of $76.9467 million as of August 13 [1] - For the fiscal year ending March 31, 2025, the company reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94%, while the net profit attributable to shareholders was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcement [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and research directions primarily cover: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2] - The laboratory located in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP; the laboratory in California has also received similar certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]